References
- http://www.cdc.gov/arthritis/basics/rheumatoid.htm. Accessed September 4, 2015
- Brooks PM. The burden of musculoskeletal disease–a global perspective. Clin Rheumatol 2006;25:778-81
- Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases, 2nd edn. New York: Oxford University Press, 2001
- Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. Arthritis Care Res (Hoboken) 2010;62:460-4
- Saag K, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2008;59:762-84
- Singh JA, Furst D, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-39
- Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011;12:204
- Smolen JS, Landewe R, Breedveld, FC. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73(3):492–509
- Meissner B, Trivedi D, You M, et al. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ 2014;17(4):259–65
- Zhang J, Shan Y, Reed G, et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large US cohort. Arth Care Res 2011;63:1672-9
- Van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007;66:849-51
- Oei HB, Hooker RS, Cipher DJ, et al. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009;27:926-34
- Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012;16:37-41
- Derose SF, Contreras R, Coleman KJ, et al. Race and ethnicity data quality and imputation using U.S. Census Data in an integrated health system: The Kaiser Permanente Southern California Experience. Med Care Res Rev 2013;70(3):330–45
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
- Kaiser Permanente. 2013 charge master list. 2013. http://xnet.kp.org/hospitalcharges/downloads/2013_CDM.pdf. Accessed February 11, 2014.
- Kaiser Permanente. 2013 sample fee list for Southern California. 2013. https://www.google.com/#q=kaiser+sample+fee+list+southern+california. Accessed February 11, 2014. (available upon reguest)
- Bonafede M, Fox KM, Johnson BH, et al. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study. Clin Therapeut 2012;34:457-67
- Harnett J, Wiederkehr D, Gerber R, et al. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis. J Med Econ 2015;27:1-12
- Hyrich KL, Lunt M, Watson KD, et al; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
- Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: resultsfrom the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47:507-13
- Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52
- Bombardieri S, Ruiz AA, Fardellone P, et al; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-9
- Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29
- Atzeni F, Sarzi-Puttini P, Gorla R, et al. Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 2011;10:397-403